- Home
- MTEK vs RDHL Comparison
MTEK vs RDHL Comparison
Compare MTEK & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTEK
- RDHL
- Stock Information
- Founded
- MTEK 2008
- RDHL 2009
- Country
- MTEK Israel
- RDHL Israel
- Employees
- MTEK N/A
- RDHL N/A
- Industry
- MTEK
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- MTEK
- RDHL Health Care
- Exchange
- MTEK Nasdaq
- RDHL Nasdaq
- Market Cap
- MTEK 14.7M
- RDHL 13.1M
- IPO Year
- MTEK 2022
- RDHL N/A
- Fundamental
- Price
- MTEK $1.92
- RDHL $8.29
- Analyst Decision
- MTEK
- RDHL
- Analyst Count
- MTEK 0
- RDHL 0
- Target Price
- MTEK N/A
- RDHL N/A
- AVG Volume (30 Days)
- MTEK 21.4K
- RDHL 34.8K
- Earning Date
- MTEK 10-15-2024
- RDHL 10-15-2024
- Dividend Yield
- MTEK N/A
- RDHL N/A
- EPS Growth
- MTEK N/A
- RDHL N/A
- EPS
- MTEK N/A
- RDHL N/A
- Revenue
- MTEK $6,967,508.00
- RDHL $3,707,000.00
- Revenue This Year
- MTEK N/A
- RDHL $224.90
- Revenue Next Year
- MTEK N/A
- RDHL $82.69
- P/E Ratio
- MTEK N/A
- RDHL N/A
- Revenue Growth
- MTEK 246.50
- RDHL N/A
- 52 Week Low
- MTEK $0.94
- RDHL $6.43
- 52 Week High
- MTEK $2.07
- RDHL $82.00
- Technical
- Relative Strength Index (RSI)
- MTEK 59.69
- RDHL 41.88
- Support Level
- MTEK $1.80
- RDHL $7.95
- Resistance Level
- MTEK $2.06
- RDHL $8.50
- Average True Range (ATR)
- MTEK 0.09
- RDHL 0.57
- MACD
- MTEK 0.01
- RDHL -0.13
- Stochastic Oscillator
- MTEK 67.37
- RDHL 11.21
About MTEK Maris-Tech Ltd.
Maris Tech Ltd is a provider of remote video, audio, telemetry acquisition, distribution, and sharing solutions and products, using high-end digital video, audio, and wireless communication technologies. It designs, develops, manufactures and commercially sells miniature intelligent video and audio surveillance and communication systems, which are offered as products and solutions for the professional as well as the civilian and home security markets.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.